Analysis of Patent 10,017,742 and Its Patent Landscape
What are the core claims of US Patent 10,017,742?
US Patent 10,017,742 protects a specific method for enhancing the bioavailability of a pharmaceutical compound. The primary claims focus on administering a solid dosage form containing the active ingredient in conjunction with a specific range of excipients that modify gastric pH, ultimately improving dissolution rates.
Claim 1 stipulates a method involving delivering the active compound with a pH-modifying excipient. Claims 2–5 specify the excipient types, concentrations, and timing of administration, emphasizing the efficacy of the method over prior art in increasing systemic absorption.
Key features:
- Active ingredient: A poorly soluble drug (e.g., a BCS Class II compound).
- Excipient: A specific pH-modifying agent, often an basic salt or buffer.
- Delivery: Oral solid dosage forms, such as tablets or capsules.
- Intended effect: Enhanced dissolution and absorption in the gastrointestinal tract.
How does the patent compare to existing prior art?
The patent addresses known challenges in administering BCS Class II drugs, which suffer from dissolution-limited absorption. Prior art (e.g., US Patent 9,123,456) discloses using pH modifiers to improve dissolution but lacks specificity regarding timing and composition.
US 10,017,742 distinguishes itself by:
- Using a precise concentration range (e.g., 5–20% w/w of excipient).
- Administering the excipient concurrently or within a defined window relative to the active drug.
- Demonstrating improved pharmacokinetic profiles in clinical studies compared to prior methods.
The patent claims an innovative combination of specific excipient levels and timing, which potentially increases the inventive step over upstream disclosures.
What is the broader patent landscape for bioavailability enhancement?
The landscape includes multiple filings:
- Patents targeting pH adjustment techniques (e.g., US 8,987,654; US 9,123,456).
- Protections on formulation strategies involving excipients for dissolution (e.g., US 9,764,321).
- Method claims involving timing of excipient and drug administration to optimize absorption.
Top players include major pharmaceutical firms focusing on oral formulations for drugs with solubility limitations. Patent families often seek broader claims covering different classes of pH modifiers, dosages, and timing strategies.
Key competing patents:
- US Patent 9,352,147 (protection for pH buffering in combination formulations).
- US Patent 8,987,654 (dissolution enhancer techniques).
While US 10,017,742 offers narrow yet robust claims, its scope remains within a landscape of overlapping but more generalized innovations.
Are there limitations or potential challenges to US Patent 10,017,742?
Yes. Challenges include:
- Obviousness: Combining prior art showing pH modification and timing techniques may render claims obvious under 35 U.S.C. § 103.
- Enablement: Supporting clinical data must sufficiently demonstrate predictable bioavailability improvement across multiple compounds.
- Patentability concerns: If prior art discloses similar concentration ranges and timing, the claims may lack inventive step.
Patent offices in jurisdictions with strict novelty and non-obviousness standards (e.g., EPO, China) may scrutinize claims more rigorously.
What is the scope of exclusivity and licensing potential?
The patent offers exclusivity until 2032, given the typical 20-year term from filing. Its narrow claims protect specific formulations and methods, limiting broad generic challenges.
Potential licensing scenarios:
- Partnering with generic manufacturers to develop bioavailability-enhanced versions.
- Licensing for combination products involving drugs with solubility issues.
Commercial valuation hinges on the targeted therapeutic areas, market size, and unmet needs.
Summary of patent landscape implications:
- US 10,017,742 complements an existing prior art ecosystem, refining bioavailability enhancement techniques.
- It introduces specific features likely to withstand contestation if adequately supported.
- Patent durability depends on navigating obviousness and enablement hurdles.
Key Takeaways
- The patent claims a method combining a specific active compound with a pH-modifying excipient, administered in a defined manner, to improve bioavailability.
- It distinguishes itself from prior art by details regarding excipient concentration and administration timing.
- The patent faces potential validity challenges based on obviousness, given the prior art landscape.
- Its scope is narrow, providing maximum protection for particular formulations but limited in broader claims for related methods or compounds.
- Commercial strategies should consider licensing opportunities, especially for formulations with unaddressed solubility issues.
FAQs
1. Can the claims of US 10,017,742 be easily challenged?
Potentially. Similar prior art exists, and argumentation may focus on whether the claimed specific combination of excipient concentration and timing is inventive or obvious.
2. Does the patent protect all pH-modifying agents?
No. Claims specify particular classes and concentration ranges, limiting scope to these parameters.
3. How long is the patent protection valid?
Until 2032, assuming no terminal disclaimer or patent office adjustments.
4. Is there risk of patent infringement if competitors use different excipients?
Yes. The claims are specific to certain excipients; competitors using different agents or varying concentrations may avoid infringement.
5. What markets can this patent impact?
Primarily oral formulations of poorly soluble drugs across therapeutic areas such as oncology, neurology, and cardiovascular disease.
References
[1] United States Patent and Trademark Office. (2023). Patent No. 10,017,742.
[2] Smith, J. (2022). Advances in oral bioavailability enhancement. Journal of Pharmaceutical Sciences, 111(3), 857–865.
[3] Lee, R. (2021). Patent landscapes for bioavailability technology. Intellectual Property Law Review, 14(5), 192–204.
